Author of

• 20152

  +

  P1.03 - Chemotherapy/Targeted Therapy (ID 689)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Chemotherapy/Targeted Therapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 22571

    +

    P1.03-016 - Video-Thoracoscopic Pulmonary Resection Avoids Delay and Increase Adjuvant Chemotherapy Compliance for Non-Small Cell Lung Carcinoma (ID 7574)

    09:30 - 09:30  |  Author(s): I. Kolbaş
    • Abstract

    Background:
    Adjuvant chemotherapy compliance and the full dose delivery of agents are believed to be superior after video-thoracoscopic lobectomy (VATS-L) for operable non-small cell lung carcinoma (NSCLC), compared with thoracotomy. The purpose of this study was to determine the role of minimally invasive lobectomy on when to start and the percentage of provided planned regimen.
    
    Method:
    All patients undergoing pulmonary resection for NSCLC between January 2010 and May 2016 were reviewed retrospectively. For comparison, analyses were performed only on patients receiving sole adjuvant chemotherapy, after the final pathology. Chemotherapy was planned according to Adjuvant Navelbine International Trialist Association (ANITA) trial. The analyzed variables were the duration between the discharged day form surgical unit and the initial chemotherapy day, the planned and the received chemotherapy doses.
    
    Result:
    Total of 74 patients were subsequently underwent adjuvant chemotherapy for NSCLC either after thoracoscopic surgery (n=26) or thoracotomy (n=48). Patients undergoing VATS-L had a shorter median length of hospital stay (4.4 versus 7.3 days; P<0.001), that leads significantly reduced time delay on chemotherapy commencement (29.4 versus 37.0 days; P=0.002). VATS-L group received 83.0% of planned Cisplatin and 81.7% of Navelbine dose. In the thoracotomy group, the compliance to planned doses of Cisplatin and Navelbine was 77.6% and 75.0%, respectively. Both of the drug regime tolerance was significantly (Cisplatin P=0.005; Navelbine P=0.020) increased in the VATS-L group (Table 1).

    Table 1. Comparison of different variables between groups
    		n		Median	SD	P*
    Hospital LOS (days)	VATS	26		4.35	1.77	<0.001
    	T	48		7.33	3.00
    %C	VATS	26		82.96	4.56	0.005
    	T	48		77.63	8.64
    %N	VATS	26		81.65	7.85	0.020
    	T	48		75.00	13.03
    Time to chemotherapy (days)	VATS	26		29.38	9.41	0.002
    	T	48		36.98	9.74
    C: Cisplatin, N: Navelbine, LOS: length of stay, SD: standard deviation, T: thoracotomy, VATS: video-assisted thoracoscopic surgery

    
    
    Conclusion:
    It is known that VATS-L has several advantages over conventional open surgery. Moreover, our data presented that it also allows more accurate and rapid adjuvant chemotherapy in terms of treatment initiation timing and compliance, by enabling quick postoperative recovery.